Pfizer’s COVID-19 vaccine: 6 things to know

{ object.primary_image.title }}

Yes, it’s very good news—yet it’s important to keep hopes and expectations in check. Nothing is certain yet. There’s some massive news out about COVID-19—and it’s good for a change. Pfizer and BioNTech’s vaccine is reportedly successful in preventing over 90% of infections according to early data from its phase 3 study , says STAT News. Needless to say, if the data holds as the study continues, this vaccine could be the thing that turns the tide of the COVID-19 pandemic in humanity’s favor. Read Full Story

Read Full Article on Fast Company

Moderna’s COVID-19 vaccine: 5 things you need to know

{ object.primary_image.title }}

Early signs are encouraging, but we need to let the science take its time and not get our hopes too high yet. Last week the world got a big dose of promising news: Pharma giant Pfizer announced early results showing its COVID-19 vaccine was effective in more than 90% of the people who received it. This week is also getting off to a good start. American biotech giant Moderna has now announced that its own COVID-19 vaccine is effective in 94.5% of the people who received it, reports The Wall Street Journal . Here’s what you need to know: Read Full Story

More

Pfizer COVID-19 vaccine update: Final results show it’s now 95% effective

{ object.primary_image.title }}

But don’t let your COVID-19 guard down yet. There’s still a long way to go before most people will receive the vaccine. Earlier this month, pharmaceutical giant Pfizer gave us some of the best news all year : Their COVID-19 vaccine was found to be effective in more than 90% of the people who received it. However, that news was preliminary, and the company was waiting on further results to see if the efficacy rating held. Read Full Story

More

How to distribute the COVID-19 vaccine: Lessons from Amazon and Walmart

{ object.primary_image.title }}

Supply-chain ideas practiced by Amazon and Walmart can help reduce waste and minimize shortages of COVID-19 vaccines. The initial rollout of Pfizer’s COVID-19 vaccine has begun, and vaccines are shipping across the U.S. Demand for COVID-19 vaccines will outpace supply for the foreseeable future. Yet experts have warned that a substantial proportion of these highly perishable vaccines could go to waste if they are not being used before they expire. Read Full Story

More

Oxford COVID-19 vaccine: Not as effective, but better than other vaccines in two big ways

{ object.primary_image.title }}

The effacacy of the Oxford vaccine is relatively low compared to Moderna’s and Pfizer’s—but it has two major advantages over its competitors. Another week and more good news in the fight against COVID-19. For the third week in a row, a successful COVID-19 has been announced—this time from researchers at Oxford University in the United Kingdom, reports the BBC. The Oxford vaccine has been one of the longest in the making—work began almost 10 months ago. However, the Oxford vaccine has a major drawback versus the American vaccines, but it also has two major advantages. Here’s what you need to know. Read Full Story

More

Subscribe to our newsletter

Join our newsletter and never miss out trending marketing news.

HitcountVariables(pk=11119, ajax_url='/api/hit/ajax/', hits='6')